📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
0 analysed today
FollowTelegram
0
Today
152,139
All-time analysed
43,645
Positive
6,747
Negative
92,898
Neutral
8,781
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
41 announcements match the current filters (relevance ≥ 5).
India Glycols FY26 PAT Jumps 26.8% to ₹293 Cr; Announces Major Three-Way Demerger Plan
India Glycols (IGL) delivered a strong performance in FY26, with consolidated Net Revenue rising 11.8% to ₹4,211 Cr and PAT increasing 26.8% to ₹293 Cr. Growth was led by the Bio-Fuel segment (+40.9% YoY) and Potable Spirits (+14.4% YoY), while the company successfully reduced finance costs and doubled its cash flow from operations to ₹769 Cr. A significant value-unlocking demerger is underway to split the business into three separate listed entities focusing on Chemicals, Spirits/Bio-fuel, and Bio-pharma, with an NCLT hearing scheduled for May 21, 2026.
Key Highlights
FY26 Consolidated EBITDA grew 24.5% YoY to ₹654 Cr with margins expanding 162 bps to 15.5%.
Bio-Fuel segment revenue surged 40.9% to ₹1,470 Cr, driven by the national 20% ethanol blending program.
Potable Spirits segment reported ₹1,331 Cr revenue with a robust 21.4% EBIT margin, supported by premiumization.
Proposed demerger ratio: 1 share of Ennature Bio Pharma for every 3 IGL shares, and 1 share of IGL Spirits for every 1 IGL share.
Finance costs for Q4FY26 dropped to ₹26 Cr from ₹45 Cr YoY, reflecting significant debt reduction through internal accruals.
👀 What to Watch
The strong operational growth combined with a clear value-unlocking demerger strategy makes this a positive outlook for long-term investors. Shareholders should monitor the NCLT proceedings on May 21 for the final approval of the restructuring.
India Glycols FY26 PAT Jumps 56.5% to ₹282 Cr; Bio-Fuel Segment Revenue Surges 41%
India Glycols reported a strong financial performance for FY26, with standalone net profit rising 56.5% to ₹282.33 crore compared to ₹180.38 crore in FY25. Annual revenue from operations grew by 8.7% to reach ₹9,826.20 crore, driven largely by the Bio-Fuel and Potable Spirits segments. The Bio-Fuel segment showed exceptional growth, with revenue increasing from ₹1,043.55 crore to ₹1,469.93 crore. EBITDA margins improved significantly, with annual EBITDA rising 32.4% to ₹690.09 crore.
Key Highlights
Standalone Net Profit for FY26 increased by 56.5% YoY to ₹282.33 crore.
Revenue from operations for the full year grew 8.7% to ₹9,826.20 crore.
Bio-Fuel segment revenue surged by 40.8% YoY to ₹1,469.93 crore in FY26.
Q4 FY26 PAT saw a massive jump of 119% YoY, reaching ₹110.28 crore compared to ₹50.35 crore in Q4 FY25.
Annual Basic EPS improved significantly to ₹44.31 from ₹29.13 in the previous year.
👀 What to Watch
Investors should monitor the continued scaling of the high-growth Bio-Fuel segment and the company's ability to maintain these expanded margins. The strong bottom-line growth and improved EPS make it a positive outlook for long-term holders.
India Glycols FY26 Net Profit Surges 56% to ₹282 Cr; Q4 Profit Jumps 119% YoY
India Glycols reported a robust financial performance for FY26, with standalone annual net profit rising 56.5% to ₹282.33 crore. The fourth quarter was particularly strong, with net profit more than doubling to ₹110.28 crore compared to ₹50.35 crore in Q4FY25. Revenue growth was steady at 8.7% for the full year, reaching ₹9,826.20 crore. The Bio-Fuel segment emerged as a key growth driver, with its annual EBIT nearly doubling to ₹115.23 crore, reflecting improved operational efficiencies and market demand.
Key Highlights
Standalone Net Profit for FY26 increased by 56.5% YoY to ₹282.33 crore.
Q4 FY26 Net Profit surged 119% YoY to ₹110.28 crore from ₹50.35 crore.
Annual Revenue from Operations grew to ₹9,826.20 crore, up from ₹9,037.82 crore in FY25.
Bio-Fuel segment EBIT saw massive growth, reaching ₹115.23 crore in FY26 vs ₹56.68 crore in FY25.
Full-year Earnings Per Share (EPS) improved significantly to ₹44.31 from ₹29.13 in the previous year.
👀 What to Watch
The significant margin expansion in the Bio-Fuel segment and strong bottom-line growth make this a positive result for shareholders. Investors should maintain a positive outlook while monitoring the scalability of the Bio-based Specialities segment.
India Glycols Demerger Update: NCLT Admits Second Motion Petition for Biopharma and Spirits Units
India Glycols Limited (IGL) has announced that the NCLT Allahabad Bench admitted its second motion petition on April 9, 2026, regarding its proposed Scheme of Arrangement. The scheme involves the demerger of business divisions into two new entities: Ennature Biopharma Limited and IGL Spirits Limited. The court has directed the company to issue statutory notices to authorities including SEBI and the Income Tax department, providing a 30-day window for representations. This procedural progress brings the company closer to completing its corporate restructuring aimed at unlocking value across its diverse business segments.
Key Highlights
NCLT Allahabad Bench admitted the Second Motion Petition for the demerger scheme on April 9, 2026.
The restructuring involves demerging assets into Ennature Biopharma Limited and IGL Spirits Limited.
Regulatory authorities and the public have been granted 30 days to file representations or objections.
The next NCLT hearing for further proceedings is scheduled for May 21, 2026.
The scheme remains subject to final regulatory approvals and the outcome of the upcoming hearing.
👀 What to Watch
Investors should view this as a positive step toward value unlocking through the separation of the biopharma and spirits businesses. Monitor the outcome of the May 21, 2026, NCLT hearing for final approval timelines.
India Glycols Unsecured Creditors Approve Demerger Scheme with 100% Majority
India Glycols Limited (IGL) has received unanimous approval from its unsecured creditors for a Scheme of Arrangement involving the demerger of businesses into Ennature Bio Pharma Limited and IGL Spirits Limited. The resolution was passed during an NCLT-convened meeting on March 24, 2026, with 100% of the polled votes in favor. This restructuring aims to separate the company's bio-pharma and spirits segments into distinct entities to potentially unlock shareholder value. The approval marks a significant milestone in the regulatory process required to finalize the corporate reorganization.
Key Highlights
Unsecured creditors approved the Scheme of Arrangement with 100% of the votes polled in favor.
The restructuring involves demerging business segments into Ennature Bio Pharma Limited and IGL Spirits Limited.
A total of 6,42,66,50,041 votes (by value) were polled during the meeting, all supporting the resolution.
The meeting was conducted via Video Conferencing as per the directions of the NCLT Allahabad Bench.
👀 What to Watch
Investors should monitor the subsequent NCLT hearings for final sanction of the scheme, which will lead to the creation of separate entities. This restructuring is likely to provide better focus on individual business segments and could lead to value unlocking for existing shareholders.
India Glycols Shareholders Approve Scheme of Arrangement with 100% Majority
Shareholders of India Glycols Limited have overwhelmingly approved a Scheme of Arrangement involving the restructuring of the company with Ennature Bio Pharma Limited and IGL Spirits Limited. In a court-convened meeting held on March 24, 2026, the special resolution received near-unanimous support, with 99.9999% of votes cast in favor. A total of 4.42 crore votes were polled, representing approximately 66.02% of the total shareholding. This restructuring is a strategic move likely aimed at separating business verticals to unlock shareholder value.
Key Highlights
Special resolution for Scheme of Arrangement passed with 4,42,48,625 votes in favor and only 1 vote against.
The arrangement involves India Glycols (Demerged Company), Ennature Bio Pharma, and IGL Spirits (Resulting Companies).
Total voting participation represented 66.02% of the company's total 6.70 crore outstanding shares.
The meeting was conducted via video conferencing following orders from the NCLT Allahabad Bench.
100% of the Promoter and Promoter Group votes (3.99 crore shares) were cast in favor of the resolution.
👀 What to Watch
Investors should view this as a positive step toward corporate restructuring and value unlocking; keep a watch for the final NCLT sanction and the record date for share allotments in the resulting companies.
India Glycols Declares ₹7.50 Interim Dividend; Sets Record Date for March 23, 2026
India Glycols Limited has declared an interim dividend of ₹7.50 per equity share (150% of face value) for the financial year 2025-26. The company has fixed March 23, 2026, as the record date to determine eligibility for the payout. Tax will be deducted at source (TDS) at a standard rate of 10% for resident individuals with a valid PAN, while a higher rate of 20% applies if the PAN is not linked with Aadhaar. Shareholders must submit relevant tax exemption documents by the record date to benefit from lower withholding rates.
Key Highlights
Interim dividend of ₹7.50 per share (150% of ₹5 face value) declared for FY 2025-26.
Record date for determining eligible shareholders is fixed as March 23, 2026.
Standard TDS of 10% for resident individuals with PAN; 20% for those without PAN or unlinked Aadhaar.
No TDS for resident individuals if the total dividend for the financial year does not exceed ₹10,000.
Non-resident shareholders may avail DTAA benefits by submitting TRC and Form 10F by the record date.
👀 What to Watch
Investors should ensure their PAN and Aadhaar are linked and submit tax-exemption forms like 15G/15H by March 23 to avoid higher TDS. To be eligible for the ₹7.50 dividend, shares must be held in the portfolio as of the record date.
India Glycols Declares Rs 7.5 Interim Dividend; Sets March 23 as Record Date
India Glycols Limited has announced an interim dividend of Rs 7.5 per equity share for the financial year 2025-26. This payout represents 150% of the face value of Rs 5 per share. The company has designated March 23, 2026, as the record date to identify eligible shareholders. The dividend is scheduled to be paid within 30 days from the declaration date of March 17, 2026.
Key Highlights
Interim dividend of Rs 7.5 per equity share declared for FY 2025-26
Dividend payout represents 150% of the face value of Rs 5 per share
Record date for shareholder eligibility fixed as March 23, 2026
Payment to be completed within 30 days from the declaration date
👀 What to Watch
Investors seeking to benefit from this dividend should ensure they hold the stock before the ex-dividend date. The 150% payout reflects a healthy cash distribution to shareholders.
India Glycols Declares Interim Dividend of Rs 7.5 Per Share (150%)
India Glycols Limited has announced an interim dividend of Rs. 7.5 per equity share for the financial year 2025-26. This payout corresponds to 150% of the face value of Rs. 5 per share. The Board has established March 23, 2026, as the record date for identifying eligible shareholders. The disbursement will occur within 30 days of the declaration date, providing a direct cash return to investors.
Key Highlights
Interim dividend of Rs. 7.5 per share declared for FY 2025-26.
Dividend payout represents 150% of the face value of Rs. 5.
Record date for shareholder eligibility set for March 23, 2026.
Payment to be completed within 30 days from March 17, 2026.
👀 What to Watch
Existing shareholders should hold their positions until the record date of March 23 to qualify for the payout. New investors interested in the dividend should ensure they purchase shares before the ex-dividend date.
India Glycols Receives Rs 38.88 Crore Interim Dividend from Clariant IGL JV
India Glycols Limited and its wholly-owned subsidiary have received a substantial interim dividend from their joint venture, Clariant IGL Specialty Chemical Private Limited. The JV declared a dividend of Rs 36,000 per share (3600%), resulting in a total gross receipt of Rs 38.88 crore for the group. Specifically, the parent company received Rs 36 crore while the subsidiary received Rs 2.88 crore. This significant cash inflow reflects the strong performance and liquidity of the joint venture entity.
Key Highlights
Total gross dividend inflow of Rs 38.88 crore from JV Clariant IGL Specialty Chemical Private Limited
JV declared an interim dividend of Rs 36,000 per equity share of face value Rs 10
India Glycols holds a 45.37% direct stake and 3.63% via a subsidiary in the JV
Net of TDS, the group received approximately Rs 34.99 crore in cash on March 17, 2026
👀 What to Watch
This is a positive development for liquidity and non-operating income; investors should monitor if these gains are passed on as dividends to IGL shareholders or used for debt reduction.
India Glycols: ₹191.76 Cr Fine Set Aside; Penalty Reduced to ₹41 Cr in Customs Case
India Glycols Limited has received a favorable appellate order regarding a customs duty dispute from March 2024. The Appellate Authority has set aside a massive redemption fine of ₹191.76 crore and reduced the penalty from ₹82 crore to ₹41 crore. While the core duty demand of ₹33.43 crore plus interest remains upheld, the total potential liability has decreased significantly. The company intends to file a second appeal to contest the remaining confirmed amounts.
Key Highlights
Redemption fine of ₹191.76 crore has been completely set aside by the Appellate Authority.
Penalty amount reduced by 50%, from ₹82 crore down to ₹41 crore.
Customs duty demand of ₹33.43 crore plus applicable interest remains upheld.
Company plans to file a second appeal against the remaining ₹74.43 crore (duty + penalty) plus interest.
👀 What to Watch
Investors should view this as a positive development as it significantly reduces a major contingent liability, though the remaining ₹74.43 crore plus interest should still be monitored through the next appeal phase.
CARE Places India Glycols on Rating Watch with Developing Implications Amid Demerger Plans
CARE Ratings has placed India Glycols' 'CARE A-' long-term rating on 'Rating Watch with Developing Implications' due to the proposed demerger of its Biofuel, Potable Spirits, and Bio-pharma businesses. The company's financial profile is improving, supported by a ₹467 crore preferential issue in Q3FY26 which was primarily used for debt reduction. Performance for 9MFY26 shows 11% revenue growth to ₹3,239 crore with margins expanding to 15.04%. The restructuring is expected to be completed within six months, resulting in three separate entities to enhance management focus.
Key Highlights
CARE A- rating placed on 'Rating Watch with Developing Implications' following the board-approved composite scheme of arrangement.
Raised ₹467 crore via preferential issue in Q3FY26, reducing total debt including LC acceptances to ₹1,793 crore as of January 2026.
9MFY26 revenue grew 11% YoY to ₹3,239 crore with PBILDT margins expanding significantly to 15.04%.
Net debt to PBILDT ratio is projected to improve to 2.5x-3.0x by FY26-end from 4.31x in FY25.
Demerger will split operations into IGL (Chemicals), IGL Spirits (Biofuels/Spirits), and Ennature Bio Pharma (Nutraceuticals).
👀 What to Watch
Investors should maintain a watch on the NCLT approval process for the demerger, which is expected to unlock value across different business segments. The substantial debt reduction and improving margins provide a positive cushion during this transition period.
India Glycols Board to Meet on March 17 to Consider Interim Dividend for FY 2025-26
India Glycols Limited has scheduled a Board of Directors meeting on March 17, 2026, to consider the declaration of an interim dividend for the financial year 2025-26. Following this announcement, the company has implemented a trading window closure for insiders from March 11 to March 19, 2026. This move indicates a potential cash payout to shareholders, reflecting the company's current financial health and commitment to returning value. Investors should watch for the specific dividend amount and record date following the meeting.
Key Highlights
Board meeting scheduled for March 17, 2026, to consider interim dividend for FY 2025-26
Trading window for securities closed from March 11, 2026, to March 19, 2026
Meeting convened under Regulation 29 of SEBI (LODR) Regulations, 2015
The outcome of the meeting will determine the dividend payout ratio for the current fiscal year
👀 What to Watch
Investors should monitor the March 17 board meeting outcome for the dividend amount and record date to assess the yield. Existing shareholders may benefit from the potential payout, while new investors should evaluate the stock's valuation relative to the dividend.
India Glycols Schedules NCLT-Convened Creditors Meeting for Demerger on March 24, 2026
India Glycols Limited (IGL) is progressing with its corporate restructuring plan to demerge businesses into Ennature Biopharma Limited and IGL Spirits Limited. Following orders from the NCLT Allahabad Bench, the company has scheduled a meeting of its unsecured creditors on March 24, 2026, to seek approval for the Scheme of Arrangement. This follows similar procedural steps for shareholders and is a mandatory regulatory requirement for the demerger to proceed. The remote e-voting for eligible creditors is set to take place between March 20 and March 23, 2026.
Key Highlights
NCLT-convened meeting of unsecured creditors scheduled for March 24, 2026, via Video Conferencing.
Scheme involves the demerger of units into two resulting companies: Ennature Biopharma Limited and IGL Spirits Limited.
Remote e-voting period is set from March 20, 2026 (9:00 AM) to March 23, 2026 (5:00 PM).
The cut-off date for determining the eligibility of unsecured creditors to vote was November 15, 2025.
👀 What to Watch
Investors should track the outcome of these meetings as the demerger will lead to the creation of specialized entities for biopharma and spirits. No immediate action is required, but the restructuring is a key milestone for potential value unlocking.
India Glycols Schedules NCLT-Convened Meeting on March 24, 2026, for Business Demerger
India Glycols Limited (IGL) has announced a Court Convened Meeting on March 24, 2026, to seek shareholder approval for a major Scheme of Arrangement. The plan involves demerging specific business undertakings into two new entities: Ennature Biopharma Limited and IGL Spirits Limited. Shareholders as of the cut-off date of March 17, 2026, will be eligible to vote on the proposal. This restructuring is intended to streamline operations and potentially unlock value for shareholders by creating focused business units.
Key Highlights
NCLT-convened meeting for equity shareholders scheduled for March 24, 2026, at 11:00 A.M. via video conferencing.
Proposed demerger of business segments into Ennature Biopharma Limited and IGL Spirits Limited.
Remote e-voting period is set from March 20, 2026, to March 23, 2026, with a cut-off date of March 17, 2026.
The scheme has already received 'No-objection' from NSE and 'No adverse observation' from BSE as of November 2025.
Special purpose financial statements for the period ending September 30, 2025, have been prepared for all involved entities.
👀 What to Watch
Investors should monitor the demerger ratio and the specific assets being transferred to evaluate the long-term value of the new entities. Shareholders are advised to participate in the e-voting process to support the corporate restructuring.
India Glycols Reschedules NCLT-Directed Shareholder Meeting to March 24, 2026
India Glycols Limited has received a revised order from the NCLT Allahabad Bench regarding its proposed Scheme of Arrangement involving Ennature Biopharma and IGL Spirits. The meetings for equity shareholders and unsecured creditors, originally set for March 9, 2026, have been rescheduled to March 24, 2026. This administrative change was necessitated by the unavailability of the NCLT-appointed Chairperson on the original date. The meetings will be conducted via video conferencing to consider and approve the restructuring scheme.
Key Highlights
NCLT Allahabad Bench approved rescheduling of shareholder and creditor meetings to March 24, 2026.
The original meeting date was March 9, 2026, but was changed due to the Chairperson's unavailability.
The Scheme of Arrangement involves India Glycols, Ennature Biopharma Limited, and IGL Spirits Limited.
Meetings will be held via video conferencing under Sections 230 to 232 of the Companies Act, 2013.
The rest of the NCLT order dated January 15, 2026, remains unchanged and valid.
👀 What to Watch
Investors should mark the new date of March 24, 2026, to participate in the voting process for the proposed demerger and arrangement. This is a routine administrative delay and does not reflect on the merits of the underlying transaction.
India Glycols Q3 FY26: Record EBITDA Growth of 36% and INR 582 Crore Debt Reduction
India Glycols Limited (IGL) reported record financial results for Q3 and 9M FY26, with 9M net revenue growing 11.4% to INR 3,235 crores. The company achieved a significant 28.9% increase in 9M EBITDA to INR 487 crores, with margins expanding to 15.0%. A major highlight was the reduction of debt by INR 582 crores during the quarter, funded by a INR 467 crore preferential allotment and internal accruals. Management remains optimistic about growth driven by premiumization in the Potable Spirits segment and high-margin Bio-based Specialty Chemicals.
Key Highlights
9M FY26 Net Revenue increased by 11.4% YoY to INR 3,235 crores, while Q3 revenue rose 13%.
EBITDA for 9M FY26 grew 28.9% to INR 487 crores, with Q3 EBITDA surging 36.1% YoY.
Total debt was reduced by INR 582 crores in Q3, significantly lowering interest obligations.
Potable Spirits segment revenue grew 17% YoY to INR 1,025 crores for the 9-month period.
9M PAT stood at INR 206 crores, representing a 23% growth compared to the previous year.
👀 What to Watch
Investors should view the aggressive deleveraging and consistent margin expansion as strong indicators of improving financial health. The strategic shift toward premium spirits and specialty chemicals suggests a sustainable improvement in the quality of earnings.
India Glycols Q3FY26 Net Profit Rises 19% to ₹68 Cr; EBITDA Margins Expand to 16%
India Glycols reported a strong Q3FY26 with net revenue growing 13% YoY to ₹1,102 crore and EBITDA surging 36% to ₹176 crore. The company achieved a significant debt reduction of ₹582 crore, primarily through a preferential allotment, which is expected to lower interest costs significantly from Q4 onwards. Segmental performance was robust, particularly in Bio-Fuels where revenue jumped 45% and Bio-Based Specialties where EBIT margins expanded to 12.8%. The Potable Spirits division continues its premiumization strategy through the Amrut partnership and expansion into new markets like Kerala and CSD.
Key Highlights
Consolidated Net Revenue for Q3FY26 grew 13% YoY to ₹1,102 Cr, while 9M PAT rose 23.4% to ₹206 Cr.
EBITDA margins expanded by 277 bps YoY to 16.0% in Q3, driven by operational efficiencies and high-margin product focus.
Total debt reduced by ₹582 Cr (₹467 Cr via preferential allotment), which will significantly reduce finance costs in future quarters.
Bio-Fuel segment revenue surged 45.2% YoY to ₹394 Cr in Q3, supported by India's 20% ethanol blending target.
Potable Spirits segment achieved 9M revenue of ₹1,025 Cr with a healthy EBIT margin of 21.2%.
👀 What to Watch
Investors should note the substantial debt reduction and margin expansion as key drivers for future profitability. The company's strategic shift toward premium spirits and high-margin specialty chemicals makes it a strong candidate for long-term growth.
India Glycols Q3 PAT Jumps 49% YoY to ₹65.26 Cr; Bio-Fuel Segment Revenue Grows 45%
India Glycols Limited (IGL) reported a robust performance for Q3 FY26, with standalone Net Profit rising 48.8% YoY to ₹65.26 crore. Revenue from operations increased 5.25% YoY to ₹2,551.06 crore, significantly supported by a 45% surge in the Bio-Fuel segment revenue. The company is actively pursuing a demerger of its Bio Pharma and Spirits & Biofuel undertakings into separate listed entities, with an appointed date of April 1, 2026. Furthermore, IGL strengthened its capital base by raising approximately ₹467 crore through a preferential allotment at ₹915 per share during the quarter.
Key Highlights
Standalone Net Profit (PAT) grew 48.8% YoY to ₹65.26 crore vs ₹43.84 crore in the previous year.
Bio-Fuel segment revenue surged 45% YoY to ₹394.28 crore from ₹271.54 crore.
Profit Before Tax (PBT) increased 51% YoY to ₹88.30 crore despite a ₹0.83 crore exceptional charge related to new labour codes.
Completed a preferential allotment of 51.03 lakh shares at ₹915 per share, raising ₹466.99 crore.
The demerger process is on track with the NCLT Allahabad Bench allowing the first motion application on January 15, 2026.
👀 What to Watch
Investors should monitor the upcoming demerger as a major value-unlocking event and track the continued high growth in the Bio-Fuel segment. The recent fundraise at ₹915 per share indicates strong institutional confidence and provides a valuation benchmark for the current market price.
India Glycols Receives NCLT Approval for First Motion of Three-Way Demerger Scheme
India Glycols Limited has received NCLT approval for the first motion of its scheme to demerge its 'Bio Pharma' and 'Spirits and Biofuel' undertakings into two separate entities, Ennature Biopharma and IGL Spirits. The NCLT has ordered meetings for equity shareholders and unsecured creditors while dispensing with meetings for secured creditors who provided 95.46% consent. Both resulting companies are intended to be listed on the NSE and BSE, aiming to unlock value and provide management focus for each distinct business segment. The appointed date for this restructuring is set for April 1, 2026.
Key Highlights
NCLT Allahabad Bench allowed the first motion for demerging Bio Pharma and Spirits & Biofuel units.
Secured creditors' meeting dispensed with after obtaining 95.46% consent in value.
Resulting entities, Ennature Biopharma and IGL Spirits, are planned to be listed on NSE and BSE.
The appointed date for the proposed Scheme of Arrangement is set as April 1, 2026.
Equity shareholders of resulting companies provided 99.94% consent, leading to meeting dispensation.
👀 What to Watch
Investors should maintain a positive outlook as the demerger is likely to unlock value by creating specialized, listed entities for the biopharma and spirits businesses. Monitor the upcoming shareholder and creditor meetings for the final approval stages.
